Stock OBI ONDINE BIOMEDICAL INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Ondine Biomedical Inc.

Equities

OBI

CA68234M2058

Market Closed - London S.E.
Other stock markets
 11:35:28 2024-05-31 am EDT 		5-day change 1st Jan Change
7 GBX -9.68% Intraday chart for Ondine Biomedical Inc. -12.50% -20.00%
May. 08 Hellenic Dynamics and Ondine Biomedical raise funds AN
May. 03 Ondine Biomedical shares rise on fundraise to advance Steriwave AN

Summary

  • On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
  • From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

  • Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
  • Analyst opinion has improved significantly over the past four months.

Weaknesses

  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Sector: Medical Equipment, Supplies & Distribution

1st Jan change Capi. Investor Rating ESG Refinitiv
ONDINE BIOMEDICAL INC. Stock Ondine Biomedical Inc.
-20.00% 24.7M -
ABBOTT LABORATORIES Stock Abbott Laboratories
-7.16% 178B
C+
MEDTRONIC PLC Stock Medtronic plc
-1.23% 107B
C
BECTON, DICKINSON AND COMPANY Stock Becton, Dickinson and Company
-4.86% 67.04B
A
DEXCOM, INC. Stock DexCom, Inc.
-4.28% 47.24B
B-
CENCORA, INC. Stock Cencora, Inc.
+10.32% 44.62B
B-
HOYA CORPORATION Stock Hoya Corporation
+8.14% 42.5B
B+
METTLER-TOLEDO INTERNATIONAL, INC. Stock Mettler-Toledo International, Inc.
+15.76% 29.99B
B
TERUMO CORPORATION Stock Terumo Corporation
+15.53% 25.22B
A-
WEST PHARMACEUTICAL SERVICES, INC. Stock West Pharmaceutical Services, Inc.
-5.88% 24.14B
A-
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
-
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality
-
  1. Stock Market
  2. Equities
  3. OBI Stock
  4. Ratings Ondine Biomedical Inc.